Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting Portfolio News / By Karina Tin October 9, 2023 Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting Read More »
Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy Portfolio News / By Karina Tin October 5, 2023 Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy Read More »
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Portfolio News / By Karina Tin October 5, 2023 Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Read More »
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration Portfolio News / By Karina Tin October 2, 2023 Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration Read More »
Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes Portfolio News / By Karina Tin September 27, 2023 Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes Read More »
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Inducible Urticaria Portfolio News / By Karina Tin September 25, 2023 Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Inducible Urticaria Read More »
Accent Therapeutics Bolsters Leadership Team with Key Executive Hires Portfolio News / By Karina Tin September 21, 2023 Accent Therapeutics Bolsters Leadership Team with Key Executive Hires Read More »
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor Portfolio News / By Karina Tin September 19, 2023 Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor Read More »
Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress Portfolio News / By Karina Tin September 11, 2023 Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress Read More »
Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics Portfolio News / By Karina Tin September 7, 2023 Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics Read More »
